Reading, United Kingdom
Archimedes Pharma, founded in 2004, is a specialty pharmaceutical company headquartered in the United Kingdom. The company's slogan, "Specialty pharmaceutical company developing therapeutics for the treatment of chronic and debilitating illnesses," encapsulates its mission to deliver pioneering treatments that address significant unmet medical needs.
Primarily operating in the Biotechnology, Health Care, and Pharmaceutical sectors, Archimedes Pharma markets a diverse portfolio targeting oncology, pain, and critical care. Initially, the firm acquired specialty products and technologies and developed a commercial platform to gain a strong foothold in the European market.
In 2010, the company secured roughly $100 million in capital, highlighting substantial investor confidence, and marked a significant growth milestone. In 2014, it received a £230 million acquisition investment from ProStrakan.
With a robust commitment to advancing patient care through innovative therapies, Archimedes Pharma positions itself as a visionary leader aiming to enhance therapeutic approaches within its specialized fields.
